Dale Boger
Corporate Officer/Principal at The Scripps Research Institute
Profile
Dale Boger is the Richard & Alice Cramer Professor at The Scripps Research Institute since 1991.
He founded Abide Therapeutics, Inc. in 2011.
Prior to his current position, he was a Faculty Member at Purdue University from 1985 to 1991 and at the University of Kansas from 1979 to 1985.
He received his doctorate degree from Harvard University in 1980 and his undergraduate degree from the University of Kansas in 1975.
Dale Boger active positions
| Companies | Position | Start |
|---|---|---|
The Scripps Research Institute
 The Scripps Research Institute Other Consumer ServicesConsumer Services The Scripps Research Institute is a private, non-profit research organizations that performs basic biomedical research in molecular & cellular biology, chemistry, immunology and neuroscience. They receive the majority of its funding from federal agencies such as the National Institutes of Health. The organization also partners with pharmaceutical companies and is affiliated with the Scripps hospital group. The organization was founded in 1955 and is headquartered in La Jolla, California. | Corporate Officer/Principal | 1990-12-31 |
Former positions of Dale Boger
| Companies | Position | End |
|---|---|---|
| Purdue University | Corporate Officer/Principal | 1990-12-31 |
| University of Kansas | Corporate Officer/Principal | 1984-12-31 |
CombiChem, Inc.
 CombiChem, Inc. Miscellaneous Commercial ServicesCommercial Services CombiChem, Inc. used to provide computational drug recovery services to accelerate the discovery process for new drugs and chemical compounds. The company was founded in 1994 and headquartered in San Diego, CA | Founder | - |
Abide Therapeutics, Inc.
 Abide Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Abide Therapeutics, Inc. develops medicines that target serine hydrolases. Its approach is to selectively block serine hydrolases, potentially expanding this class of commercially validated enzymes as targets in a range of indications. The firm has a technology platform that exploits a chemoproteomics approach to selectively target serine hydrolases and rapidly identify target lead pairs. The company was founded by Alan B. Ezekowitz, Dale Boger, John Kennedy Clarke, Benjamin F. Cravatt, Todd Jones, Keith F. Lenden, and Paul R. Schimmel in 2011 and is headquartered in San Diego, CA. | Founder | - |
Training of Dale Boger
| University of Kansas | Undergraduate Degree |
| Harvard University | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 2 |
|---|---|
Abide Therapeutics, Inc.
Abide Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Abide Therapeutics, Inc. develops medicines that target serine hydrolases. Its approach is to selectively block serine hydrolases, potentially expanding this class of commercially validated enzymes as targets in a range of indications. The firm has a technology platform that exploits a chemoproteomics approach to selectively target serine hydrolases and rapidly identify target lead pairs. The company was founded by Alan B. Ezekowitz, Dale Boger, John Kennedy Clarke, Benjamin F. Cravatt, Todd Jones, Keith F. Lenden, and Paul R. Schimmel in 2011 and is headquartered in San Diego, CA. | Health Technology |
CombiChem, Inc.
CombiChem, Inc. Miscellaneous Commercial ServicesCommercial Services CombiChem, Inc. used to provide computational drug recovery services to accelerate the discovery process for new drugs and chemical compounds. The company was founded in 1994 and headquartered in San Diego, CA | Commercial Services |
- Stock Market
- Insiders
- Dale Boger